Search
Now showing items 41-47 of 47
Multiple myeloma: family history and mortality in second primary cancers.
(NATURE PUBLISHING GROUP, 2018-08-07)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
(AMER ASSOC CANCER RESEARCH, 2019-01-01)
PURPOSE: Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory activities. This first-in-human phase I study (NCT01421524) ...
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
(ELSEVIER SCIENCE INC, 2017-06-17)
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ...
Genomic Evolution of Breast Cancer Metastasis and Relapse.
(CELL PRESS, 2017-08-14)
Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ...
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
(ELSEVIER SCIENCE INC, 2014-09-01)
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Behçet's syndrome. In March ...
The Influence of Antireflux Surgery on Esophageal Cancer Risk in England: National Population-based Cohort Study.
(2018-11)
Objective To evaluate how antireflux surgery influences the risk of esophageal cancer in patients with gastroesophageal reflux disease (GERD) and Barrett esophagus.Background GERD is a major risk factor for esophageal ...
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
(NATURE PORTFOLIO, 2017-01-06)
Despite advancements in the use of transcriptional information to understand and classify breast cancers, the contribution of splicing to the establishment and progression of these tumours has only recently starting to ...